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Abstract
Background: Recent studies have shown that high expression levels of class I histone deacetylases (HDACs) correlate with
malignant phenotype and poor prognosis in some human tumors. However, the expression patterns and prognostic role of
class I HDAC isoforms in hepatocellular carcinoma (HCC) remain unclear.
Methodology/Principal Findings: The expression patterns and clinical significance of class I HDAC isoforms were assessed
by immunohistochemistry in a cohort of 43 hepatitis B virus-associated HCC patients treated with liver transplantation. In
addition, the effects of HDAC inhibition on HCC cell behavior were investigated by knockdown of the HDAC isoform with
short interfering RNA. Class I HDACs were highly expressed in a subset of HCCs with positivity for HDAC1 in 51.2%, HDAC2
in 48.8%, and HDAC3 in 32.6% of cases. The expression levels of HDAC isoforms were significantly associated with the
proliferation index of HCC. Kaplan-Meier curves showed that a high expression level of HDAC2 or HDAC3 implicated
significantly reduced recurrence-free survival. Cox proportional hazards model analysis revealed HDAC3 overexpression was
an unfavorable independent prognostic factor (P=0.002; HR 3.907). In vitro, inhibition of HDAC2 and HDAC3, but not
HDAC1, suppressed proliferation and the invasiveness of liver cancer cells.
Conclusions/Significance: Our findings demonstrate that HDAC3 plays a significant role in regulating tumor cell
proliferation and invasion, and it could be served as a candidate biomarker for predicting the recurrence of hepatitis B virus-
associated HCC following liver transplantation and a potential therapeutic target.
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Introduction
Hepatocellular carcinoma (HCC) is the most common primary
malignant tumor in liver. It ranks fifth in incidence and fourth in
mortality rate in overall tumors [1,2]. China is one of the highest
prevalent areas of HCC, mainly because chronic hepatitis B
carriers account for more than 10% of the Chinese population [3].
The prognosis of patients with HCC is generally poor, even after
surgery or chemotherapy. Liver transplantation (LT) offers a
potential curative option for patients with small HCC. However,
frequent recurrence or metastasis after transplantation remains the
main obstacle for long-term survival [4]. Therefore, elucidating
the molecular mechanism of HCC recurrence is vital for the
development of more effective therapeutic strategies.
Evidence has shown that modifications of acetylation play an
important role in tumor progression and metastasis [5,6]. Histone
deacetylases (HDACs) are known to be one of the major enzymes
that change the nucleosomal conformation of tumor cells via post-
translational deacetylation of the core histones. Therefore, aberrant
activation of HDACs leads to transcriptional repression of diverse
genes mainly involved in the regulation of behavior of tumor cells
such as proliferation, differentiation, angiogenesis and invasion, as
well as migration and metastasis [7,8].
So far, eighteen HDAC isoforms, grouped into four classes,
have been described in humans [9]. Among them, the best
characterized and probably biologically most relevant HDACs
were class I isoforms HDAC1, HDAC2 and HDAC3. The ex-
pression patterns of HDAC1, HDAC2 and HDAC3 have been
evaluated in different types of cancers, including gastric cancer
[10], colorectal cancer [11], prostate cancer [12], breast cancer
[13], renal cell cancer [14], and ovarian and endometrial car-
cinomas [15]. Elevated expression of class I HDAC has been
shown to be an unfavorable independent prognostic factor in some of
these tumor entities [16]. However, little is known on the expression
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especially in HCC treated with LT.
Recently, a new group of chemotherapeutics called histone
deacetylase inhibitors (HDIs) have emerged. HDIs, such as
valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA)
target the HDAC enzyme family. VPA and SAHA, inhibiting class
I and class II HDACs, causes growth arrest, differentiation and/or
apoptosis of tumor cells, and considered to be potential substances
for the treatment of malignant solid human tumors in the near
future [17,18]. However, the contribution of specific HDAC
isoforms to the tumor progression, invasion and metastasis is still
unclear.
In the present study, we investigated the expression patterns of
HDAC1, HDAC2 and HDAC3 in HCC patients following LT
and analyzed their relationship to the clinical phenotype, using a
clinically well-characterized cohort of HCC patients treated with
LT. Meanwhile, the functions of specific class I HDAC isoforms in
liver cancer cells were also characterized.
Methods
Ethics statement
The study protocol was approved by the Institutional Review
Board of Key Lab of Combined Multi-organ Transplantation,
Ministry of Public Health. Informed written consent was obtained
according to the Declaration of Helsinki.
Study population and tissue samples
Forty-three HCC patients treated with LT during 2003 and
2005 in our hospital (First Affiliated Hospital, Zhejiang University
School of Medicine, Zhejiang, China) were enrolled in this study.
The eligibility criteria for the patients studied are as follows: (a)
HCC diagnosed either before or after transplantation (as an
incidental finding), which was confirmed by histopathological
examination; (b) the patients were Han Chinese; (c) complete
clinical and laboratory data such as portal vein tumor thrombi
(PVTT), preoperative alpha-fetoprotein(AFP) level, histopatholog-
ic grading, tumor size, and tumor number were available before
operation and during follow-up; (d) all patients were HBV-positive
(HBsAg+) and none of them were hepatitis C virus (HCV)-positive;
(e) none of the patients received preoperative adjuvant antineo-
plastic therapy; and (f) absence of de novo HCC nodules occurring
in the transplanted liver. Follow-up data were obtained after LT
for all 43 patients. The follow-up course and diagnostic criteria of
recurrence has been described previously [19]. The distribution of
the clinicopathologic data in the study cohort is given in
Supplementary Table S1.
Cell lines
Liver cancer cell lines SMMC-7721 and HepG2, as well as the
metastasis-capable human HCC cell lines MHCC97L (interme-
diate metastatic capability) and HCCLM3 (the most metastatic
capability) were purchased from American Type Culture Collec-
tion (Manassas, VA) and Shanghai Institute of Cell Biology
(Shanghai, China).All of the cell lines were maintained in the
recommended culture conditions and incubated at 37uCi na
humidified environment containing 5% CO2.
Immunohistochemistry
Tissue sections of 4-mm thickness were stained with monoclonal
mouse HDAC1 antibody (1:80; Abcam, Cambridge, UK),
monoclonal mouse HDAC2 antibody (1:5000; Abcam), monoclo-
nal rabbit HDAC3 antibody (1:80; Abcam) and monoclonal
mouse Ki-67 antibody (1:100; Zhongshan, Beijing, China). The
immunohistochemistry procedure has been described previously
[20]. Nuclear staining of HDAC1, HDAC2 and HDAC3 was
scored using a semi-quantitative immunoreactivity scoring (IRS)
system [11]. The immunostained sections were independently
evaluated by two pathologists who were blind to the clinical data.
Cases with an IRS from 0 to 6 were defined as HDAC negative,
while cases with an IRS higher than 6 were defined as HDAC
positive. The Ki-67 index was determined by counting Ki-67-
positive nuclei per 100 tumor cells in a representative tumor section.
HDIs treatment and RNA interference
Cells were seeded into plates with a density of 5610
4/mL,
cultured for 24 hours, then treated with SAHA(Alexis Biochemicals,
San Diego, CA) and VPA (Sigma, St.Louis, MO) at a concentration
of 2.5 mM and 2 mM, respectively. After evaluating the effects of
chemical HDI, we analyzed the specific function of Class I HDAC
isoforms in liver cancer cells. Select validated short interfering RNA
(siRNA) duplexes (Ambion, Austin, TX) were used to detect RNA
interference-mediated down-regulation of HDAC1, 2, 3, and a
nonsilencing siRNA was used as negative control. After 24 hours,
cells were transfected with 33 nM siRNA using Lipofectamine2000
transfection reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’sinstructions. Theefficacyoftransfection was checked
by Reverse Transcription Polymerase Chain Reaction (RT-PCR)
after 48 hours of incubation.
Cell viability assay and cell cycle analysis
Following treatment with HDIs or siRNA for 72 hours, cell
viability was detected using a cell counting kit-8 (Dojindo
Laboratories, Kumamoto, Japan) according to the manufacturer’s
instructions. Cells were then incubated at 37uC for another
2 hours and measured at 450 nm and 630 nm. The experiment
was repeated three times.
To detect the cell cycle alterations, cells were treated with
HDAC1, 2, 3 siRNA, VPA and SAHA as described above. Cells
were then harvested and stained with DNA PREP kit (Beckman
Coulter, Fullerton, CA). The percentage of cells in sub G1, G0/G1,
S, and G2/M phase was quantified using flow cytometry analysis
according to the manufacturer’s instructions (CYTOMICS FC 500,
Beckman Coulter). The extent of apoptosis was assessed by the
proportion of cells giving fluorescence in the hypodiploid sub G1
peak of the cell cycle. Analysis of cell cycle data was done with
MULTICYCLE analysis software. All experiments were done in
triplicates.
Cell invasion assay
Cell invasion analysis was performed using a Transwell
(Millipore, Billerica, MA) based method. Seventy-two hours after
RNA interference, 200 mL of 0.8610
5 cells were applied to the
upper compartment of the matrigel (BD Bioscience, San Jose, CA)
coated filters, while the lower compartment was filled with
Dulbecco’s modified Eagle’s medium supplemented with 15% fetal
bovine serum. After 48 hours, migrated cells on the bottom surface
werefixedwith methanol and stained with0.1%CrystalViolet.The
invading cells were examined, counted, and photographed using
digital microscopy (6200). Four fields were counted per filter in
each group.
Semiquantitative reverse-transcription polymerase chain
reaction
Total RNA was extracted from all the cell lines using TRIZOL
(Invitrogen, Carlsbad, CA). Two micrograms of total RNA was
used for cDNA synthesis in each reaction. PCR were performed
HDAC3 in HCC
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listed on Supplementary Table S2. Relative gel band intensities of
the products were measured by Kodak digital science image
system (Kodak, Rochester, NY).
Statistical analysis
The association between Class I HDAC expression and
clinicopathological variables was assessed by using either the
Pearson’s chi-square test or two sided Fisher’s exact test, as
appropriate. The correlation of Class I HDAC expression and
tumor recurrence was evaluated according to Kaplan-Meier
estimates. Cox regression was applied to assess variables signi-
ficantly associated to recurrence in the univariate analysis. The
detailed statistical tests used in the study are given in Results, and
in the Tables and Figure legends. Statistical analysis was
performed with SPSS 15.0 and GraphPad Prism 5.0. All tests
were two tailed and P,0.05 was considered statistically significant.
Results
Expression patterns of Class I HDAC isoforms in HCC
High expression levels of all three HDAC isoforms (HDAC1,
HDAC2 and HDAC3) in HCC nuclear were observed. In 43 cases,
22 (51.2%), 21 (48.8%) and 14 (32.6%) cases were positive for
HDAC1, HDAC2 and HDAC3, respectively (Supplementary
Table S1; Figure 1A). In some cases, additional cytoplasmic
positivitywasobserved ina minorityoftumorcells.Furthermore,all
of the three HDAC isoforms were detectable in the nuclei of the bile
duct. Stromal cellsof HCCalso displayedweak tomoderate nuclear
positivity for all of the three HDAC isoforms, which might be dueto
positive staining in fibroblasts and infiltrating inflammatory cells.
Correlation of Class I HDAC isoforms expression with
clinicopathologic variables and cell proliferation
The association of the expression levels of HDAC isoform with
clinicopathologic variables were further analyzed. Resultantly, the
expression level of HDAC1 and HDAC2 was only associated with
Ki-67 index (HDAC1, P=0.021; HDAC2, P=0.044), while
HDAC3 was associated with Ki-67 index (P=0.001) and tumor
size (P=0.005) (Supplementary Table S1). In addition, when the
patients were grouped according to their overall class I HDAC
expression pattern (all three isoforms negative versus one or two
isoforms positive versus all three isoforms positive), positive
expression of all three isoforms was associated with enhanced
Ki-67 index as a surrogate marker of proliferation (P,0.001, one
way ANOVA) and tumor size .5 cm (P=0.033, x
2 test for trends;
Supplementary Table S1).
Correlation of Class I HDAC isoforms expression and
recurrence
To determine whether changes in class I HDAC expression were
relevant to the recurrence of HCC patients treated with LT,
univariate and multivariate survival analysis were performed.
Patients with a high expression level of HDAC2 or HDAC3 were
prone to earlier recurrence of HCC according to Kaplan-Meier
estimates (Table 1, Figure 1B). Furthermore, we observed that the
difference was pronounced when the HDAC all positive expression
group was compared with HDAC all negative expression group
(P=0.015; Figure 1B). Univariate analysis also revealed that the
clinicopathological variables could provide significant predictive
values for recurrence including PVTT (P=0.024), preoperative
AFP level (P=0.004), tumor size (P=0.004), and tumor number
(P=0.017) (Table 1). These results were consistent with those
previous reports in terms of clinical histological features [19,21],
which suggests that the selected samples in this study reflect the
characteristics of LT patients in the Chinese population. Multivar-
iate analysis further revealed that HDAC3 expression level was a
novel independent factor (P=0.002; hazard ratio 3.907) for
predicting recurrence-free survival (Table 2).
Inhibition of cell proliferation and cell cycle alterations by
treatment with VPA and SAHA
In vitro, we tested the effects of chemical HDI on liver cancer
cells (SMMC-7721, HepG2, MHCC97L and HCCLM3). Treat-
ment of liver cancer cells with SAHA (maximum dose 5 mM) and
Table 1. Influence of HDAC isoform expression and
clinicopathologic variables on HCC recurrence.
Variables Grading Recur P*
Negative Positive
Age(Years) #50 9 13 0.278
.50 12 9
Gender Female 1 1 0.788
Male 20 21
PVTT Negative 16 10 0.024
Positive 5 12
Preoperative AFP
level (ng/ml)
#400 15 8 0.004
.400 6 14
Histopathologic
grading
Well+moderate 17 16 0.884
Poor 4 6
Tumor size (cm) #5 12 4 0.004
.59 1 8
Tumor number Single 12 5 0.017
Multiple 9 17
HDAC1 Negative 13 8 0.228
Positive 8 14
HDAC2 Negative 16 6 0.010
Positive 5 16
HDAC3 Negative 19 10 0.001
Positive 2 12
HDAC groups All negative 10 5 0.015
Partially positive 10 6
All positive 1 11
*Log-rank test.
doi:10.1371/journal.pone.0014460.t001
Figure 1. The role of class I HDAC expression in HCC patients receiving liver transplantation. (A) Representative HDAC1-positive (a,b),
HDAC2-positive(c,d) and HDAC3-positive(e,f) samples are shown at 1006(a,c,e) and 4006magnification (b,d,f). HDAC negative (IRS from 0 to 6) and
HDAC positive (IRS higher than 6). (B) Kaplan-Meier curves estimates the recurrence-free survival rates according to expression patterns of HDAC1, 2,
3, and combined HDAC expression in the cohort.
doi:10.1371/journal.pone.0014460.g001
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dependent reduction in cell number after 72 hours (Figure 2A).
In addition, treatment of liver cancer cell lines with VPA (2 mM,
48 or 72 hours) resulted in an accumulation of cells in G0-G1 phase
of the cell cycle. In contrast, treatment with SAHA (2.5 mM, 48 or
72 hours) led to an accumulation of cells in the G2-M phase
(Figure 3A; Supplementary Table S3). Meanwhile, treatment with
SAHA, and to a lesser extent of VPA, led to a significant induction
of apoptosis of liver cancer cells in a time-dependent manner.
Inhibition of cell proliferation and cell cycle alterations by
specific silencing Class I HDAC isoforms
To further understand the function of Class I HDAC isoforms
in liver cancer cells, specific class I HDAC isoforms were
knockdowned by siRNA in HepG2 cell. The data showed that
treatment with selective siRNA led to a specific reduction of
mRNA expression of the HDAC isoforms (Figure 2B). In addition,
selective knockdown of HDAC1, HDAC2 and HDAC3 resulted in
a reduction of 5.3%, 19.7% and 29.7% in cell number, respectively.
However, only the difference for HDAC2 and HDAC3 was
statistically significant (P,0.05; Figure 2C).
Similarly, knockdown of HDAC2 and HDAC3 in HepG2
resulted in an accumulation of cells in G2-M and a reduction of
cells in the S phase (Figure 3B; Supplementary Table S3), while
specific knockdown of HDAC1 showed no obvious effect on the
cell cycle after 48 hours. No significant induction of apoptosis in
HepG2 was observed after treatment with isoform-specific siRNA
in the present study (Figure 3B).
Inhibition of invasion of HCC cells by specific silencing
Class I HDAC isoforms
As shown in Figure 4C, the inhibitory efficiency of siRNAs for
gene transcription was significant in high-metastasic potential
HCCLM3 cells. To determine whether knockdown of specific
HDAC isoform had a crucial role in cell invasion, we performed
Figure 2. Antiproliferative effects of chemical HDAC inhibitors and selective HDAC1, 2, 3 silencing in HCC cells. (A) Treatment with
either VPA or SAHA led to a significant dose-dependent reduction of HCC cell numbers after 72 h. (B) Effective silencing of HDAC1, 2, 3 mRNA in
HepG2 after siRNA treatment for 48 hours. (C) Selective knockdown of HDAC3 and HDAC2 led to reduction of HepG2 cell numbers after 72 hours
(**P,0.01, Student t test).
doi:10.1371/journal.pone.0014460.g002
Table 2. Multivariate Cox regression analysis of variables
related to tumor recurrence at univariate analysis.
Variable HR(95% CI) P
AFP
,400 ng/ml 1.000
.400 ng/ml 3.520(1.441–8.598) 0.006
HDAC3
Negative 1.000
Positive 3.907(1.623–9.403) 0.002
Abbreviations: HR, risk ratio; 95% CI, 95% confidence interval.
doi:10.1371/journal.pone.0014460.t002
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number of invaded cells transfected with HDAC2 or HDAC3
siRNA significantly decreased when compared to those with
negative control siRNA (Figure 4A, B). This indicates that the
invasive potential of HCCLM3 cells was suppressed after
transfection of HDAC2 and HDAC3 siRNA. In line with the
hypothesis that HDAC2 and HDAC3 may be important
contributors to the invasion of tumor cells, the expression levels
of HDAC2 and HDAC3 influenced the metastatic behavior of the
HCCLM3 cell line.
Discussion
In the present study, class I HDAC isoforms (HDAC1,
HDAC2, and HDAC3) were highly expressed in a panel of
HCC cases. High expression levels of HDAC2 and HDAC3 were
associated with significantly reduced recurrence-free survival,
with HDAC3 being an independent prognostic factor in this
cohort. In addition, respective silencing of HDAC2 and HDAC3
suppressed proliferation and the invasiveness of HCC cell lines
in vitro. To our knowledge, this is the first detailed systematic
Figure 3. Apoptosis-inducing and cellcycle alteration effects of HDIs and selective HDAC siRNA silencing in HCC. (A) Flow cytometric
analysis of apoptosis and cell cycle in 4 HCC cell lines after the treatment with the DMSO vehicle or the indicated concentrations of VPA and SAHA for
24, 48, or 72 hours. (B) Apoptosis and cellcycle alterations in HepG2 after selective silencing of HDAC1, 2, 3 for 48 hours.
doi:10.1371/journal.pone.0014460.g003
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proteins in HCC.
Increasing numbers of studies suggest that expression of class I
HDACs is associated with clinicopathological parameters or tumor
prognosis in several types of cancer [10–12]. In a study of prostate
cancer, Weichert et al [12] demonstrated that high expression
levels of class I HDACs correlated with higher proliferative
fractions (measured by Ki-67). Similar results were also observed
in the present study. Expression of HDAC1 (P=0.021),
HDAC2(P=0.044) and HDAC3 (P=0.001) were all associated
with the Ki-67 index of liver cancer cells (Supplementary Table
S1). These data suggest that high HDAC activity leads to
enhanced tumor cell activity. Based on these findings, we
speculated that the expression level of class I HDACs might be
associated with tumor recurrence in LT patients for HCC. We
found that expression of HDAC3 was an independent factor
influencing the risk of recurrence in HCC patients following LT,
which is in line with the in vitro results of proliferation, cell cycle,
and invasion (Figure 2, Figure 4). These data suggest HDAC3
expression may serve as a novel candidate prognosticator for HCC
treated with LT, although the finding ought to be verified in a
larger prospective study.
On the other hand, the functional studies of liver cell lines with
siRNAs targeting class I HDACs showed no obvious difference
between the knockdown of HDAC2 or HADC3 expression in the
amount of viable cells, as well as in the amount of invasive cells.
Some recent studies also have demonstrated that high HDAC2
expression is associated with shortened relapse-free survival time
or overall survival time in different types of cancer [10,12].
However, in the present study, only HDAC3, not HDAC2 showed
an independent specific role in predicting recurrence of HCC
following liver transplantation. This discrepancy might be due to
the small sample size, which is similar to most of the cohorts
previously investigated.
In addition, elevated HDAC1 expression showed no influence
on the risk of recurrent HCC after LT in the present study, which
is contrast to the previous study for 47 Japanese patients with
surgically resected HCC [22]. Possible explanations for the
discrepancy in these results include difference in the studied
cohorts, including variation in the genetic and etiology back-
grounds of the patients. Despite the important role of HDAC3 in
tumor recurrence and its predictive implications, this study should
be viewed as hypothesis generating, to be followed by larger
prospective and multiethnic studies to confirm our findings.
Figure 4. Alteration of class I HDAC isoform levels in HCCLM3 cells changes its invasiveness in vitro. (A) Selective knockdown of HDAC3
and HDAC2 led to reduced invasiveness of HCCLM3 (**P,0.01, Student t test). (B) Representative images of invasiveness of HCCLM3 cells transfected
with negative siRNA (a) or siRNA against HDAC1(b), HDAC2(c), and HDAC3 (d). The transwell invasion assay showed that HCCLM3 cells transfected
with siRNA against HDAC2,3 displayed a markedly decreased invasiveness behavior, as indicated by a significant decrease in the average number of
cells invaded through the matrigel in comparison with the control siRNA. (C) Effective silencing of HDAC1, 2, 3 mRNA in HCCLM3 after siRNA
treatment for 48 hours.
doi:10.1371/journal.pone.0014460.g004
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and SAHA) could reduce cell proliferation, induce cell cycle arrest
and apoptosis of several liver cancer cell lines [23–25]. Obviously,
our results confirmed these effects in a range of liver cancer cells.
However, current data on the cellular effects of a specific HDAC
isoform knockdown in liver cancer is unclear. To clarify whether
the effects of VPA and SAHA inhibition could be contributed to
an inhibitory effect on one specific class I HDAC isoform, we
investigated the effect of HDAC1, HDAC2, or HDAC3 on the
proliferation, cell cycle, apoptosis and invasion of HCC cells by
means of RNA silencing. Consistent with the above mentioned
results in vivo (Supplementary Table S1), we found that silencing of
HDAC2 or HDAC3 significantly reduced cell numbers and
induced cell cycle arrest in HepG2 cells, suggesting that selected
class I HDAC isoforms may play an important role in regulating
tumor cell proliferation. Supporting our results, a previously
published study demonstrated similar effects in colon cancer cell
lines [26]. In addition, similar to the results of Spurling et al [27] in
SW480 cells, the invasive capacity of HCCLM3 cells was
significantly reduced after HDAC2 or HDAC3 knockdown,
indicating that these two isoforms are involved in the invasion
and metastasis processes of HCC cells. In the preset study, we
chose HCCLM3 as the representative HCC cell line to analyze the
invasiveness influence of HDACs, therefore, the observed results
and mechanisms might be limited to this cell line. We can get
more detailed data by evaluating additional metastatic potential
cell lines, such as MHCC97L and MHCC97H. Taken together,
these findings suggest that HDAC2 and HDAC3, especially
HDAC3, may be important regulators for the proliferation and
invasion of HCC cells, which at least partly explained the
mechanism of tumor recurrence in vivo, and could be possible
targets for suppressing tumor viability.
Our findings confirm the cellular biological basis that Class I
HDACs exert a tumor-promoter effect in HCC through the
induction of cell proliferation, invasion and metastasis. HCC cell
proliferation and invasion involves in multiple steps and required
alterations of a variety of tumor related genes, such as CDKN1A,
E-cadherin, T-cadherin, DACT3, and MMP-2 [26,28–30]. To
comprehensively understand the exact molecular mechanism of
the class I HDACs regulation, gene expression microarray analysis
involving tumor proliferation and metastasis pathways, should be
conducted.
The HBV contribution for the current findings should be
highlighted in the present study. Recently, the induction of HDAC1
by HBV X protein has been reported [31,32], and could act as a
confounding factor. In the present study, the studied population
almost unavoidably consisted of patients with hepatitis B virus-
associated HCC because of the special situation in China. The
analysis of HDACs expression in liver tissue of HCC patients with
other etiological backgrounds might be very useful to ascertain the
real predictive value of HDAC3 for HCC recurrence.
In summary, our results demonstrated the important role of
class I HDACs, especially HDAC3, in liver cancer biology.
Patients showing elevated HDAC3 expression had a significant
negative prognostic impact in terms of recurrence-free survival,
which indicates the potential use of this molecular marker to
predict patient risk of recurrence after LT. More importantly, the
prognostic impact of HDACs, together with our observation of the
proposed interactions of HDAC isoforms with tumor cell
proliferation and invasion, strongly suggests targeting class I
HDACs might be an effective therapeutic strategy for HCC
patients after LT.
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